Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

8089 items
11:02 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...
10:08 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Tetraphase launches Xerava in the U.S.

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) launched Xerava eravacycline in the U.S. to treat complicated intra-abdominal infections (cIAIs) in adults at a wholesale acquisition cost (WAC) of $175 per day. According to its U.S. label, Xerava is...
11:29 AM, Oct 12, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER issues final report for hATTR therapies with recommendations

ICER released its final evidence report on treatments for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) recommending that insurers and payers develop prior authorization criteria for Onpattro patisiran and Tegsedi inotersen, and that manufacturers bring prices down...
10:56 AM, Oct 12, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NHS, Gilead reach agreement for Yescarta

NHS England said it will cover Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. (NASDAQ:GILD) through the Cancer Drugs Fund (CDF), making Yescarta the first CAR T available to adults in England. Last month, NHS England struck...
10:56 AM, Oct 12, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Vertex reaches agreements with Denmark, Austria over access to CF drugs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it has entered into an contract with Amgros, Denmark's pharmaceutical procurement organization, for access to the biotech's cystic fibrosis portfolio. The agreement includes current and future CF drugs. Vertex's approved drugs...
11:44 AM, Sep 28, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Gilead targets Medicaid with launch of HCV generics

Gilead Sciences Inc. (NASDAQ:GILD) hopes a plan to launch authorized generics of two HCV drugs will lower out-of-pocket costs for patients and increase its share in the Medicaid population. But the head of Medicaid Health...
10:57 AM, Sep 28, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report, the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies despite...
10:39 AM, Sep 28, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Indivior slashes Sublocade guidance on payer friction

Indivior plc (LSE:INDV) fell 42.40p (16%) to 215p on Sept. 26 when it sharply lowered its 2018 revenue guidance for Sublocade buprenorphine, saying it “substantially underestimated” how long it would take for payers to approve...
9:28 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE waivers on end of life exception for DLBCL CAR Ts, says Kymriah doesn't meet criteria

Inconsistencies between appraisals by U.K.'s NICE of CAR T therapies emerged Sept. 19 after the committee released draft guidance that said Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) does not qualify as a life-extending treatment...
9:24 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Sorrento's Scilex launching ZTlido in October

Scilex Pharmaceuticals Inc. (San Diego, Calif.), a subsidiary of Sorrento Therapeutics Inc. (NASDAQ:SRNE), expects to launch ZTlido 1.8% lidocaine patch in October at a wholesale acquisition cost (WAC) of $8.98 per patch. FDA approved the...

Pages